HomeCompareEPMV vs JNJ

EPMV vs JNJ: Dividend Comparison 2026

EPMV yields 1.47% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPMV wins by $1.8K in total portfolio value
10 years
EPMV
EPMV
● Live price
1.47%
Share price
$22.68
Annual div
$0.33
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.8K
Annual income
$161.85
Full EPMV calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — EPMV vs JNJ

📍 EPMV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPMVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPMV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPMV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPMV
Annual income on $10K today (after 15% tax)
$125.06/yr
After 10yr DRIP, annual income (after tax)
$137.57/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, JNJ beats the other by $566.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPMV + JNJ for your $10,000?

EPMV: 50%JNJ: 50%
100% JNJ50/50100% EPMV
Portfolio after 10yr
$20.9K
Annual income
$494.81/yr
Blended yield
2.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EPMV
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPMV buys
0
JNJ buys
0
No recent congressional trades found for EPMV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPMVJNJ
Forward yield1.47%3.36%
Annual dividend / share$0.33$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$21.8K$20.0K
Annual income after 10y$161.85$827.78
Total dividends collected$1.6K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EPMV vs JNJ ($10,000, DRIP)

YearEPMV PortfolioEPMV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,847$147.13$10,676$355.77+$171.00EPMV
2$11,756$149.16$11,407$389.39+$349.00EPMV
3$12,730$151.07$12,198$426.53+$532.00EPMV
4$13,774$152.89$13,056$467.62+$718.00EPMV
5$14,892$154.60$13,987$513.12+$905.00EPMV
6$16,091$156.22$14,998$563.56+$1.1KEPMV
7$17,375$157.76$16,098$619.52+$1.3KEPMV
8$18,751$159.20$17,295$681.69+$1.5KEPMV
9$20,224$160.56$18,599$750.82+$1.6KEPMV
10$21,801$161.85$20,022$827.78+$1.8KEPMV

EPMV vs JNJ: Complete Analysis 2026

EPMVStock

Harbor Mid Cap Value ETF (EPMV) is a series of the Harbor ETF Trust. The fund seeks long-term total return by investing primarily in equity securities, principally common stocks, of U.S. mid-cap companies that are, in the subadviser’s opinion, out of favor and undervalued at the time of purchase. The ETF uses a systematic, quantitative approach to identify deep-value stocks and aims to provide diversified exposure to the U.S. mid-cap value segment. The fund is managed by LSV Asset Management, known for its academic, risk-aware, and systematic value investing discipline

Full EPMV Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this EPMV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPMV vs SCHDEPMV vs JEPIEPMV vs OEPMV vs KOEPMV vs MAINEPMV vs ABBVEPMV vs MRKEPMV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.